nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—hematologic cancer—muscle cancer	0.475	1	CtDrD
Imatinib—KIT—muscle cancer	0.245	1	CbGaD
Imatinib—ABCG2—Dactinomycin—muscle cancer	0.0192	0.133	CbGbCtD
Imatinib—ABCG2—Vincristine—muscle cancer	0.0118	0.0819	CbGbCtD
Imatinib—ABCG2—Etoposide—muscle cancer	0.0108	0.0751	CbGbCtD
Imatinib—PTGS1—Etoposide—muscle cancer	0.01	0.0693	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—muscle cancer	0.00913	0.0633	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00873	0.0605	CbGbCtD
Imatinib—CYP3A7—Vincristine—muscle cancer	0.00873	0.0605	CbGbCtD
Imatinib—ABCG2—Doxorubicin—muscle cancer	0.00739	0.0512	CbGbCtD
Imatinib—ABCG2—Methotrexate—muscle cancer	0.00716	0.0496	CbGbCtD
Imatinib—ABCB1—Dactinomycin—muscle cancer	0.00692	0.048	CbGbCtD
Imatinib—CYP3A5—Vincristine—muscle cancer	0.00655	0.0454	CbGbCtD
Imatinib—CYP3A5—Etoposide—muscle cancer	0.006	0.0416	CbGbCtD
Imatinib—ALB—Methotrexate—muscle cancer	0.00493	0.0342	CbGbCtD
Imatinib—CYP1A2—Etoposide—muscle cancer	0.00447	0.031	CbGbCtD
Imatinib—ABCB1—Vincristine—muscle cancer	0.00426	0.0295	CbGbCtD
Imatinib—ABCB1—Etoposide—muscle cancer	0.00391	0.0271	CbGbCtD
Imatinib—ABCB1—Doxorubicin—muscle cancer	0.00266	0.0185	CbGbCtD
Imatinib—ABCB1—Methotrexate—muscle cancer	0.00258	0.0179	CbGbCtD
Imatinib—CYP3A4—Vincristine—muscle cancer	0.00255	0.0177	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—muscle cancer	0.00251	0.0174	CbGbCtD
Imatinib—CYP3A4—Etoposide—muscle cancer	0.00234	0.0162	CbGbCtD
Imatinib—CYP3A4—Doxorubicin—muscle cancer	0.0016	0.0111	CbGbCtD
Imatinib—Ponatinib—KIT—muscle cancer	0.0012	0.575	CrCbGaD
Imatinib—Nilotinib—KIT—muscle cancer	0.000882	0.425	CrCbGaD
Imatinib—DDR1—smooth muscle tissue—muscle cancer	0.00072	0.0236	CbGeAlD
Imatinib—DDR1—cardiac atrium—muscle cancer	0.000621	0.0203	CbGeAlD
Imatinib—NTRK1—testis—muscle cancer	0.000614	0.0201	CbGeAlD
Imatinib—ABCA3—tendon—muscle cancer	0.000586	0.0192	CbGeAlD
Imatinib—ABCA3—vagina—muscle cancer	0.000544	0.0178	CbGeAlD
Imatinib—DDR1—tendon—muscle cancer	0.000541	0.0177	CbGeAlD
Imatinib—ABCA3—head—muscle cancer	0.000503	0.0164	CbGeAlD
Imatinib—DDR1—vagina—muscle cancer	0.000502	0.0164	CbGeAlD
Imatinib—HIPK4—testis—muscle cancer	0.000491	0.0161	CbGeAlD
Imatinib—ABCA3—testis—muscle cancer	0.000485	0.0159	CbGeAlD
Imatinib—DDR1—testis—muscle cancer	0.000448	0.0147	CbGeAlD
Imatinib—CA7—renal system—muscle cancer	0.000445	0.0146	CbGeAlD
Imatinib—PDGFRA—embryo—muscle cancer	0.000414	0.0136	CbGeAlD
Imatinib—PIP4K2C—cardiac atrium—muscle cancer	0.000383	0.0125	CbGeAlD
Imatinib—CA3—cardiac atrium—muscle cancer	0.000366	0.012	CbGeAlD
Imatinib—CSF1R—embryo—muscle cancer	0.000365	0.0119	CbGeAlD
Imatinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000355	0.333	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000355	0.333	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000355	0.333	CbGdCrCtD
Imatinib—ABL2—tendon—muscle cancer	0.000353	0.0116	CbGeAlD
Imatinib—PIP4K2C—tendon—muscle cancer	0.000334	0.0109	CbGeAlD
Imatinib—CA14—cardiac atrium—muscle cancer	0.000332	0.0109	CbGeAlD
Imatinib—KIT—embryo—muscle cancer	0.000331	0.0108	CbGeAlD
Imatinib—ABL2—vagina—muscle cancer	0.000328	0.0107	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—muscle cancer	0.000326	0.0107	CbGeAlD
Imatinib—PIP4K2C—bone marrow—muscle cancer	0.000323	0.0106	CbGeAlD
Imatinib—PDGFRB—embryo—muscle cancer	0.000323	0.0106	CbGeAlD
Imatinib—CA3—tendon—muscle cancer	0.000319	0.0104	CbGeAlD
Imatinib—NQO2—renal system—muscle cancer	0.000314	0.0103	CbGeAlD
Imatinib—PDGFRA—renal system—muscle cancer	0.000313	0.0103	CbGeAlD
Imatinib—PIP4K2C—vagina—muscle cancer	0.00031	0.0101	CbGeAlD
Imatinib—CA3—bone marrow—muscle cancer	0.000309	0.0101	CbGeAlD
Imatinib—CA9—tendon—muscle cancer	0.000305	0.00999	CbGeAlD
Imatinib—SLC22A2—renal system—muscle cancer	0.000298	0.00974	CbGeAlD
Imatinib—CA3—vagina—muscle cancer	0.000296	0.00969	CbGeAlD
Imatinib—ABL2—testis—muscle cancer	0.000292	0.00957	CbGeAlD
Imatinib—CA14—tendon—muscle cancer	0.00029	0.00948	CbGeAlD
Imatinib—CA12—renal system—muscle cancer	0.000289	0.00947	CbGeAlD
Imatinib—CA6—head—muscle cancer	0.000289	0.00945	CbGeAlD
Imatinib—ABL1—embryo—muscle cancer	0.000288	0.00943	CbGeAlD
Imatinib—LCK—bone marrow—muscle cancer	0.000287	0.0094	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—muscle cancer	0.000287	0.00938	CbGeAlD
Imatinib—PIP4K2C—head—muscle cancer	0.000286	0.00937	CbGeAlD
Imatinib—NQO2—cardiac atrium—muscle cancer	0.000281	0.00921	CbGeAlD
Imatinib—PIP4K2C—testis—muscle cancer	0.000277	0.00905	CbGeAlD
Imatinib—LCK—vagina—muscle cancer	0.000275	0.009	CbGeAlD
Imatinib—CA3—head—muscle cancer	0.000273	0.00895	CbGeAlD
Imatinib—CA3—testis—muscle cancer	0.000264	0.00864	CbGeAlD
Imatinib—KIT—smooth muscle tissue—muscle cancer	0.00026	0.00852	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—muscle cancer	0.000254	0.00832	CbGeAlD
Imatinib—CA9—testis—muscle cancer	0.000253	0.00827	CbGeAlD
Imatinib—SLC47A1—renal system—muscle cancer	0.000252	0.00825	CbGeAlD
Imatinib—KIT—renal system—muscle cancer	0.000251	0.0082	CbGeAlD
Imatinib—CSF1R—cardiac atrium—muscle cancer	0.000247	0.00809	CbGeAlD
Imatinib—LCK—testis—muscle cancer	0.000245	0.00803	CbGeAlD
Imatinib—NQO2—tendon—muscle cancer	0.000245	0.00803	CbGeAlD
Imatinib—PDGFRB—renal system—muscle cancer	0.000245	0.00801	CbGeAlD
Imatinib—PDGFRA—tendon—muscle cancer	0.000245	0.00801	CbGeAlD
Imatinib—NQO2—bone marrow—muscle cancer	0.000238	0.00778	CbGeAlD
Imatinib—CA1—renal system—muscle cancer	0.000229	0.0075	CbGeAlD
Imatinib—NQO2—vagina—muscle cancer	0.000228	0.00745	CbGeAlD
Imatinib—PDGFRA—vagina—muscle cancer	0.000227	0.00743	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—muscle cancer	0.000227	0.00742	CbGeAlD
Imatinib—PDGFRB—cardiac atrium—muscle cancer	0.000219	0.00717	CbGeAlD
Imatinib—ABL1—renal system—muscle cancer	0.000218	0.00714	CbGeAlD
Imatinib—CSF1R—tendon—muscle cancer	0.000215	0.00705	CbGeAlD
Imatinib—SLC22A1—renal system—muscle cancer	0.00021	0.00688	CbGeAlD
Imatinib—NQO2—head—muscle cancer	0.00021	0.00688	CbGeAlD
Imatinib—PDGFRA—head—muscle cancer	0.00021	0.00686	CbGeAlD
Imatinib—CSF1R—bone marrow—muscle cancer	0.000209	0.00683	CbGeAlD
Imatinib—NQO2—testis—muscle cancer	0.000203	0.00665	CbGeAlD
Imatinib—PDGFRA—testis—muscle cancer	0.000203	0.00663	CbGeAlD
Imatinib—CSF1R—vagina—muscle cancer	0.0002	0.00654	CbGeAlD
Imatinib—SLC47A1—tendon—muscle cancer	0.000197	0.00644	CbGeAlD
Imatinib—CA2—embryo—muscle cancer	0.000196	0.00642	CbGeAlD
Imatinib—ABL1—cardiac atrium—muscle cancer	0.000195	0.00639	CbGeAlD
Imatinib—CA12—head—muscle cancer	0.000194	0.00634	CbGeAlD
Imatinib—PDGFRB—tendon—muscle cancer	0.000191	0.00625	CbGeAlD
Imatinib—KIT—bone marrow—muscle cancer	0.000189	0.0062	CbGeAlD
Imatinib—PDGFRB—bone marrow—muscle cancer	0.000185	0.00606	CbGeAlD
Imatinib—CSF1R—head—muscle cancer	0.000185	0.00604	CbGeAlD
Imatinib—SLC47A1—vagina—muscle cancer	0.000183	0.00598	CbGeAlD
Imatinib—KIT—vagina—muscle cancer	0.000181	0.00594	CbGeAlD
Imatinib—CSF1R—testis—muscle cancer	0.000178	0.00584	CbGeAlD
Imatinib—PDGFRB—vagina—muscle cancer	0.000177	0.0058	CbGeAlD
Imatinib—ORM1—bone marrow—muscle cancer	0.000174	0.00568	CbGeAlD
Imatinib—CA1—bone marrow—muscle cancer	0.000173	0.00567	CbGeAlD
Imatinib—ABL1—tendon—muscle cancer	0.00017	0.00557	CbGeAlD
Imatinib—SLC47A1—head—muscle cancer	0.000169	0.00552	CbGeAlD
Imatinib—KIT—head—muscle cancer	0.000168	0.00549	CbGeAlD
Imatinib—ABL1—bone marrow—muscle cancer	0.000165	0.0054	CbGeAlD
Imatinib—PDGFRB—head—muscle cancer	0.000164	0.00536	CbGeAlD
Imatinib—SLC47A1—testis—muscle cancer	0.000163	0.00533	CbGeAlD
Imatinib—KIT—testis—muscle cancer	0.000162	0.0053	CbGeAlD
Imatinib—PDGFRB—testis—muscle cancer	0.000158	0.00518	CbGeAlD
Imatinib—ABL1—vagina—muscle cancer	0.000158	0.00517	CbGeAlD
Imatinib—CA2—smooth muscle tissue—muscle cancer	0.000154	0.00505	CbGeAlD
Imatinib—CA1—head—muscle cancer	0.000153	0.00502	CbGeAlD
Imatinib—SLC22A1—vagina—muscle cancer	0.000152	0.00499	CbGeAlD
Imatinib—CA2—renal system—muscle cancer	0.000149	0.00486	CbGeAlD
Imatinib—ABL1—head—muscle cancer	0.000146	0.00478	CbGeAlD
Imatinib—ABL1—testis—muscle cancer	0.000141	0.00461	CbGeAlD
Imatinib—SLC22A1—head—muscle cancer	0.000141	0.00461	CbGeAlD
Imatinib—CA2—cardiac atrium—muscle cancer	0.000133	0.00435	CbGeAlD
Imatinib—CYP1A2—renal system—muscle cancer	0.000132	0.00433	CbGeAlD
Imatinib—ALB—testis—muscle cancer	0.00013	0.00426	CbGeAlD
Imatinib—CYP3A5—renal system—muscle cancer	0.000128	0.00418	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—muscle cancer	0.000119	0.0039	CbGeAlD
Imatinib—CYP2C19—vagina—muscle cancer	0.000117	0.00384	CbGeAlD
Imatinib—CA2—tendon—muscle cancer	0.000116	0.00379	CbGeAlD
Imatinib—PTGS1—renal system—muscle cancer	0.000115	0.00376	CbGeAlD
Imatinib—CA2—bone marrow—muscle cancer	0.000112	0.00368	CbGeAlD
Imatinib—CA2—vagina—muscle cancer	0.000108	0.00352	CbGeAlD
Imatinib—ABCG2—bone marrow—muscle cancer	0.000104	0.0034	CbGeAlD
Imatinib—PTGS1—cardiac atrium—muscle cancer	0.000103	0.00336	CbGeAlD
Imatinib—ABCG2—vagina—muscle cancer	9.96e-05	0.00326	CbGeAlD
Imatinib—CA2—head—muscle cancer	9.94e-05	0.00325	CbGeAlD
Imatinib—CA2—testis—muscle cancer	9.6e-05	0.00314	CbGeAlD
Imatinib—CYP3A4—renal system—muscle cancer	9.58e-05	0.00314	CbGeAlD
Imatinib—CYP2D6—renal system—muscle cancer	9.43e-05	0.00309	CbGeAlD
Imatinib—CYP3A5—vagina—muscle cancer	9.25e-05	0.00303	CbGeAlD
Imatinib—ABCB1—embryo—muscle cancer	8.96e-05	0.00293	CbGeAlD
Imatinib—PTGS1—tendon—muscle cancer	8.95e-05	0.00293	CbGeAlD
Imatinib—ABCG2—testis—muscle cancer	8.89e-05	0.00291	CbGeAlD
Imatinib—PTGS1—vagina—muscle cancer	8.31e-05	0.00272	CbGeAlD
Imatinib—PTGS1—head—muscle cancer	7.68e-05	0.00251	CbGeAlD
Imatinib—PTGS1—testis—muscle cancer	7.41e-05	0.00243	CbGeAlD
Imatinib—ABCB1—renal system—muscle cancer	6.78e-05	0.00222	CbGeAlD
Imatinib—CYP2D6—head—muscle cancer	6.31e-05	0.00207	CbGeAlD
Imatinib—CYP2D6—testis—muscle cancer	6.09e-05	0.00199	CbGeAlD
Imatinib—Tachycardia—Etoposide—muscle cancer	5.64e-05	0.00097	CcSEcCtD
Imatinib—Abdominal pain—Vincristine—muscle cancer	5.64e-05	0.00097	CcSEcCtD
Imatinib—Body temperature increased—Vincristine—muscle cancer	5.64e-05	0.00097	CcSEcCtD
Imatinib—Skin disorder—Etoposide—muscle cancer	5.61e-05	0.000965	CcSEcCtD
Imatinib—Erectile dysfunction—Methotrexate—muscle cancer	5.6e-05	0.000964	CcSEcCtD
Imatinib—Dry skin—Doxorubicin—muscle cancer	5.59e-05	0.000961	CcSEcCtD
Imatinib—Hyperhidrosis—Etoposide—muscle cancer	5.58e-05	0.000961	CcSEcCtD
Imatinib—Abdominal pain upper—Doxorubicin—muscle cancer	5.57e-05	0.000958	CcSEcCtD
Imatinib—Photosensitivity reaction—Methotrexate—muscle cancer	5.55e-05	0.000955	CcSEcCtD
Imatinib—Hypokalaemia—Doxorubicin—muscle cancer	5.55e-05	0.000954	CcSEcCtD
Imatinib—Breast disorder—Doxorubicin—muscle cancer	5.51e-05	0.000947	CcSEcCtD
Imatinib—Anorexia—Etoposide—muscle cancer	5.51e-05	0.000947	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	5.49e-05	0.000944	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	5.49e-05	0.000944	CcSEcCtD
Imatinib—Diarrhoea—Dactinomycin—muscle cancer	5.46e-05	0.000939	CcSEcCtD
Imatinib—Pneumonia—Methotrexate—muscle cancer	5.46e-05	0.000939	CcSEcCtD
Imatinib—Nasopharyngitis—Doxorubicin—muscle cancer	5.45e-05	0.000938	CcSEcCtD
Imatinib—Infestation NOS—Methotrexate—muscle cancer	5.43e-05	0.000933	CcSEcCtD
Imatinib—Infestation—Methotrexate—muscle cancer	5.43e-05	0.000933	CcSEcCtD
Imatinib—Depression—Methotrexate—muscle cancer	5.41e-05	0.00093	CcSEcCtD
Imatinib—Hypotension—Etoposide—muscle cancer	5.4e-05	0.000928	CcSEcCtD
Imatinib—Gastritis—Doxorubicin—muscle cancer	5.4e-05	0.000928	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	5.38e-05	0.000925	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	5.38e-05	0.000925	CcSEcCtD
Imatinib—Muscular weakness—Doxorubicin—muscle cancer	5.38e-05	0.000925	CcSEcCtD
Imatinib—Renal failure—Methotrexate—muscle cancer	5.33e-05	0.000917	CcSEcCtD
Imatinib—Abdominal distension—Doxorubicin—muscle cancer	5.3e-05	0.000912	CcSEcCtD
Imatinib—Stomatitis—Methotrexate—muscle cancer	5.29e-05	0.00091	CcSEcCtD
Imatinib—Conjunctivitis—Methotrexate—muscle cancer	5.27e-05	0.000907	CcSEcCtD
Imatinib—Influenza—Doxorubicin—muscle cancer	5.27e-05	0.000906	CcSEcCtD
Imatinib—Dysphagia—Doxorubicin—muscle cancer	5.27e-05	0.000906	CcSEcCtD
Imatinib—Hypersensitivity—Vincristine—muscle cancer	5.25e-05	0.000904	CcSEcCtD
Imatinib—Eosinophilia—Doxorubicin—muscle cancer	5.22e-05	0.000897	CcSEcCtD
Imatinib—Sweating—Methotrexate—muscle cancer	5.2e-05	0.000895	CcSEcCtD
Imatinib—Paraesthesia—Etoposide—muscle cancer	5.19e-05	0.000892	CcSEcCtD
Imatinib—Haematuria—Methotrexate—muscle cancer	5.17e-05	0.00089	CcSEcCtD
Imatinib—Pancreatitis—Doxorubicin—muscle cancer	5.17e-05	0.000888	CcSEcCtD
Imatinib—Dyspnoea—Etoposide—muscle cancer	5.15e-05	0.000886	CcSEcCtD
Imatinib—Somnolence—Etoposide—muscle cancer	5.14e-05	0.000883	CcSEcCtD
Imatinib—Angina pectoris—Doxorubicin—muscle cancer	5.13e-05	0.000883	CcSEcCtD
Imatinib—Hepatobiliary disease—Methotrexate—muscle cancer	5.13e-05	0.000883	CcSEcCtD
Imatinib—ABCB1—bone marrow—muscle cancer	5.13e-05	0.00168	CbGeAlD
Imatinib—Epistaxis—Methotrexate—muscle cancer	5.12e-05	0.00088	CcSEcCtD
Imatinib—Asthenia—Vincristine—muscle cancer	5.12e-05	0.00088	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—muscle cancer	5.08e-05	0.000873	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—muscle cancer	5.06e-05	0.000871	CcSEcCtD
Imatinib—Rash—Dactinomycin—muscle cancer	5.03e-05	0.000866	CcSEcCtD
Imatinib—Decreased appetite—Etoposide—muscle cancer	5.02e-05	0.000864	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—muscle cancer	5e-05	0.000861	CcSEcCtD
Imatinib—Gastrointestinal disorder—Etoposide—muscle cancer	4.99e-05	0.000858	CcSEcCtD
Imatinib—Fatigue—Etoposide—muscle cancer	4.98e-05	0.000857	CcSEcCtD
Imatinib—Constipation—Etoposide—muscle cancer	4.94e-05	0.00085	CcSEcCtD
Imatinib—Pain—Etoposide—muscle cancer	4.94e-05	0.00085	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—muscle cancer	4.93e-05	0.000847	CcSEcCtD
Imatinib—ABCB1—vagina—muscle cancer	4.91e-05	0.00161	CbGeAlD
Imatinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	4.9e-05	0.000842	CcSEcCtD
Imatinib—Haemoglobin—Methotrexate—muscle cancer	4.9e-05	0.000842	CcSEcCtD
Imatinib—Diarrhoea—Vincristine—muscle cancer	4.88e-05	0.000839	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—muscle cancer	4.87e-05	0.000838	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—muscle cancer	4.87e-05	0.000838	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—muscle cancer	4.87e-05	0.000837	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—muscle cancer	4.83e-05	0.000831	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—muscle cancer	4.81e-05	0.000827	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—muscle cancer	4.81e-05	0.000827	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—muscle cancer	4.8e-05	0.000825	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—muscle cancer	4.77e-05	0.000821	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—muscle cancer	4.77e-05	0.00082	CcSEcCtD
Imatinib—Feeling abnormal—Etoposide—muscle cancer	4.76e-05	0.000819	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—muscle cancer	4.75e-05	0.000817	CcSEcCtD
Imatinib—Nausea—Dactinomycin—muscle cancer	4.74e-05	0.000815	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—muscle cancer	4.73e-05	0.000813	CcSEcCtD
Imatinib—Gastrointestinal pain—Etoposide—muscle cancer	4.72e-05	0.000812	CcSEcCtD
Imatinib—Dizziness—Vincristine—muscle cancer	4.72e-05	0.000811	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—muscle cancer	4.7e-05	0.000808	CcSEcCtD
Imatinib—Infestation—Doxorubicin—muscle cancer	4.7e-05	0.000808	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	4.66e-05	0.000801	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—muscle cancer	4.62e-05	0.000794	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—muscle cancer	4.61e-05	0.000792	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—muscle cancer	4.61e-05	0.000792	CcSEcCtD
Imatinib—Urticaria—Etoposide—muscle cancer	4.59e-05	0.000789	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—muscle cancer	4.58e-05	0.000788	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—muscle cancer	4.58e-05	0.000788	CcSEcCtD
Imatinib—Body temperature increased—Etoposide—muscle cancer	4.57e-05	0.000785	CcSEcCtD
Imatinib—Abdominal pain—Etoposide—muscle cancer	4.57e-05	0.000785	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—muscle cancer	4.57e-05	0.000785	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—muscle cancer	4.57e-05	0.000785	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—muscle cancer	4.55e-05	0.000783	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—muscle cancer	4.54e-05	0.000781	CcSEcCtD
Imatinib—ABCB1—head—muscle cancer	4.54e-05	0.00149	CbGeAlD
Imatinib—Vomiting—Vincristine—muscle cancer	4.53e-05	0.00078	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—muscle cancer	4.52e-05	0.000777	CcSEcCtD
Imatinib—Sweating—Doxorubicin—muscle cancer	4.5e-05	0.000775	CcSEcCtD
Imatinib—Rash—Vincristine—muscle cancer	4.5e-05	0.000773	CcSEcCtD
Imatinib—Dermatitis—Vincristine—muscle cancer	4.49e-05	0.000773	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—muscle cancer	4.48e-05	0.00077	CcSEcCtD
Imatinib—Headache—Vincristine—muscle cancer	4.47e-05	0.000768	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—muscle cancer	4.44e-05	0.000764	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—muscle cancer	4.43e-05	0.000762	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—muscle cancer	4.42e-05	0.00076	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—muscle cancer	4.41e-05	0.000758	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—muscle cancer	4.4e-05	0.000757	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—muscle cancer	4.39e-05	0.000755	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—muscle cancer	4.38e-05	0.000754	CcSEcCtD
Imatinib—ABCB1—testis—muscle cancer	4.38e-05	0.00144	CbGeAlD
Imatinib—Chills—Methotrexate—muscle cancer	4.37e-05	0.000752	CcSEcCtD
Imatinib—Alopecia—Methotrexate—muscle cancer	4.3e-05	0.00074	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—muscle cancer	4.27e-05	0.000734	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—muscle cancer	4.26e-05	0.000732	CcSEcCtD
Imatinib—Erythema—Methotrexate—muscle cancer	4.24e-05	0.000729	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—muscle cancer	4.24e-05	0.000729	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—muscle cancer	4.24e-05	0.000729	CcSEcCtD
Imatinib—Nausea—Vincristine—muscle cancer	4.24e-05	0.000729	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—muscle cancer	4.23e-05	0.000727	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—muscle cancer	4.22e-05	0.000725	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—muscle cancer	4.22e-05	0.000725	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—muscle cancer	4.2e-05	0.000722	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—muscle cancer	4.19e-05	0.00072	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—muscle cancer	4.16e-05	0.000716	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—muscle cancer	4.15e-05	0.000715	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—muscle cancer	4.15e-05	0.000714	CcSEcCtD
Imatinib—Asthenia—Etoposide—muscle cancer	4.14e-05	0.000713	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—muscle cancer	4.14e-05	0.000713	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—muscle cancer	4.13e-05	0.000711	CcSEcCtD
Imatinib—Back pain—Methotrexate—muscle cancer	4.1e-05	0.000705	CcSEcCtD
Imatinib—Pruritus—Etoposide—muscle cancer	4.09e-05	0.000703	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—muscle cancer	4e-05	0.000687	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—muscle cancer	3.99e-05	0.000686	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—muscle cancer	3.95e-05	0.00068	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—muscle cancer	3.94e-05	0.000678	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—muscle cancer	3.93e-05	0.000677	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—muscle cancer	3.93e-05	0.000676	CcSEcCtD
Imatinib—Anaemia—Methotrexate—muscle cancer	3.92e-05	0.000674	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—muscle cancer	3.91e-05	0.000673	CcSEcCtD
Imatinib—Flushing—Doxorubicin—muscle cancer	3.91e-05	0.000673	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—muscle cancer	3.83e-05	0.000658	CcSEcCtD
Imatinib—Malaise—Methotrexate—muscle cancer	3.82e-05	0.000658	CcSEcCtD
Imatinib—Dizziness—Etoposide—muscle cancer	3.82e-05	0.000657	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—muscle cancer	3.81e-05	0.000655	CcSEcCtD
Imatinib—Vertigo—Methotrexate—muscle cancer	3.81e-05	0.000655	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—muscle cancer	3.8e-05	0.000654	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—muscle cancer	3.8e-05	0.000653	CcSEcCtD
Imatinib—Chills—Doxorubicin—muscle cancer	3.78e-05	0.000651	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—muscle cancer	3.77e-05	0.000648	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—muscle cancer	3.73e-05	0.000641	CcSEcCtD
Imatinib—Cough—Methotrexate—muscle cancer	3.7e-05	0.000636	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—muscle cancer	3.69e-05	0.000635	CcSEcCtD
Imatinib—Convulsion—Methotrexate—muscle cancer	3.67e-05	0.000632	CcSEcCtD
Imatinib—Vomiting—Etoposide—muscle cancer	3.67e-05	0.000632	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—muscle cancer	3.67e-05	0.000631	CcSEcCtD
Imatinib—Erythema—Doxorubicin—muscle cancer	3.67e-05	0.000631	CcSEcCtD
Imatinib—Rash—Etoposide—muscle cancer	3.64e-05	0.000626	CcSEcCtD
Imatinib—Dermatitis—Etoposide—muscle cancer	3.64e-05	0.000626	CcSEcCtD
Imatinib—Headache—Etoposide—muscle cancer	3.62e-05	0.000622	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—muscle cancer	3.62e-05	0.000622	CcSEcCtD
Imatinib—Chest pain—Methotrexate—muscle cancer	3.61e-05	0.000621	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—muscle cancer	3.61e-05	0.000621	CcSEcCtD
Imatinib—Myalgia—Methotrexate—muscle cancer	3.61e-05	0.000621	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—muscle cancer	3.6e-05	0.000618	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.58e-05	0.000617	CcSEcCtD
Imatinib—Discomfort—Methotrexate—muscle cancer	3.57e-05	0.000613	CcSEcCtD
Imatinib—Back pain—Doxorubicin—muscle cancer	3.55e-05	0.000611	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—muscle cancer	3.53e-05	0.000607	CcSEcCtD
Imatinib—Confusional state—Methotrexate—muscle cancer	3.49e-05	0.0006	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—muscle cancer	3.46e-05	0.000595	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—muscle cancer	3.46e-05	0.000595	CcSEcCtD
Imatinib—Infection—Methotrexate—muscle cancer	3.44e-05	0.000591	CcSEcCtD
Imatinib—Nausea—Etoposide—muscle cancer	3.43e-05	0.00059	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—muscle cancer	3.41e-05	0.000586	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—muscle cancer	3.39e-05	0.000584	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—muscle cancer	3.39e-05	0.000584	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—muscle cancer	3.39e-05	0.000583	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—muscle cancer	3.36e-05	0.000578	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—muscle cancer	3.35e-05	0.000575	CcSEcCtD
Imatinib—Malaise—Doxorubicin—muscle cancer	3.31e-05	0.000569	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—muscle cancer	3.3e-05	0.000567	CcSEcCtD
Imatinib—Anorexia—Methotrexate—muscle cancer	3.3e-05	0.000567	CcSEcCtD
Imatinib—Syncope—Doxorubicin—muscle cancer	3.29e-05	0.000566	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—muscle cancer	3.29e-05	0.000565	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—muscle cancer	3.24e-05	0.000558	CcSEcCtD
Imatinib—Hypotension—Methotrexate—muscle cancer	3.23e-05	0.000556	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—muscle cancer	3.23e-05	0.000555	CcSEcCtD
Imatinib—Cough—Doxorubicin—muscle cancer	3.2e-05	0.000551	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—muscle cancer	3.18e-05	0.000547	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—muscle cancer	3.17e-05	0.000545	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.15e-05	0.000542	CcSEcCtD
Imatinib—Insomnia—Methotrexate—muscle cancer	3.13e-05	0.000538	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—muscle cancer	3.13e-05	0.000538	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—muscle cancer	3.13e-05	0.000538	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—muscle cancer	3.13e-05	0.000538	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—muscle cancer	3.11e-05	0.000536	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—muscle cancer	3.11e-05	0.000534	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.1e-05	0.000534	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—muscle cancer	3.09e-05	0.000531	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—muscle cancer	3.08e-05	0.000531	CcSEcCtD
Imatinib—Somnolence—Methotrexate—muscle cancer	3.08e-05	0.000529	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—muscle cancer	3.06e-05	0.000526	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—muscle cancer	3.05e-05	0.000524	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—muscle cancer	3.02e-05	0.00052	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—muscle cancer	3.01e-05	0.000517	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—muscle cancer	3e-05	0.000515	CcSEcCtD
Imatinib—Oedema—Doxorubicin—muscle cancer	3e-05	0.000515	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—muscle cancer	2.99e-05	0.000514	CcSEcCtD
Imatinib—Fatigue—Methotrexate—muscle cancer	2.98e-05	0.000513	CcSEcCtD
Imatinib—Infection—Doxorubicin—muscle cancer	2.98e-05	0.000512	CcSEcCtD
Imatinib—Pain—Methotrexate—muscle cancer	2.96e-05	0.000509	CcSEcCtD
Imatinib—Shock—Doxorubicin—muscle cancer	2.95e-05	0.000507	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—muscle cancer	2.94e-05	0.000505	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—muscle cancer	2.93e-05	0.000505	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—muscle cancer	2.92e-05	0.000503	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—muscle cancer	2.91e-05	0.000501	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—muscle cancer	2.9e-05	0.000498	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—muscle cancer	2.86e-05	0.000491	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—muscle cancer	2.85e-05	0.00049	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—muscle cancer	2.83e-05	0.000487	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—muscle cancer	2.8e-05	0.000482	CcSEcCtD
Imatinib—Urticaria—Methotrexate—muscle cancer	2.75e-05	0.000473	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—muscle cancer	2.74e-05	0.00047	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—muscle cancer	2.74e-05	0.00047	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.73e-05	0.00047	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—muscle cancer	2.71e-05	0.000466	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—muscle cancer	2.69e-05	0.000463	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—muscle cancer	2.67e-05	0.000459	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—muscle cancer	2.66e-05	0.000458	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—muscle cancer	2.64e-05	0.000454	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—muscle cancer	2.6e-05	0.000448	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.59e-05	0.000445	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—muscle cancer	2.58e-05	0.000444	CcSEcCtD
Imatinib—Constipation—Doxorubicin—muscle cancer	2.56e-05	0.000441	CcSEcCtD
Imatinib—Pain—Doxorubicin—muscle cancer	2.56e-05	0.000441	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—muscle cancer	2.55e-05	0.000438	CcSEcCtD
Imatinib—Asthenia—Methotrexate—muscle cancer	2.48e-05	0.000427	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—muscle cancer	2.47e-05	0.000425	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—muscle cancer	2.45e-05	0.000421	CcSEcCtD
Imatinib—Pruritus—Methotrexate—muscle cancer	2.45e-05	0.000421	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—muscle cancer	2.38e-05	0.000409	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—muscle cancer	2.37e-05	0.000407	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—muscle cancer	2.37e-05	0.000407	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—muscle cancer	2.37e-05	0.000407	CcSEcCtD
Imatinib—Dizziness—Methotrexate—muscle cancer	2.29e-05	0.000394	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—muscle cancer	2.21e-05	0.00038	CcSEcCtD
Imatinib—Vomiting—Methotrexate—muscle cancer	2.2e-05	0.000378	CcSEcCtD
Imatinib—Rash—Methotrexate—muscle cancer	2.18e-05	0.000375	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—muscle cancer	2.18e-05	0.000375	CcSEcCtD
Imatinib—Headache—Methotrexate—muscle cancer	2.17e-05	0.000373	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—muscle cancer	2.15e-05	0.00037	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—muscle cancer	2.12e-05	0.000365	CcSEcCtD
Imatinib—Nausea—Methotrexate—muscle cancer	2.06e-05	0.000354	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—muscle cancer	2.05e-05	0.000353	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—muscle cancer	1.98e-05	0.000341	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—muscle cancer	1.91e-05	0.000328	CcSEcCtD
Imatinib—Rash—Doxorubicin—muscle cancer	1.89e-05	0.000325	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—muscle cancer	1.89e-05	0.000325	CcSEcCtD
Imatinib—PDGFRA—Immune System—CD34—muscle cancer	1.88e-05	0.000428	CbGpPWpGaD
Imatinib—Headache—Doxorubicin—muscle cancer	1.88e-05	0.000323	CcSEcCtD
Imatinib—NTRK1—Circadian rythm related genes—TP53—muscle cancer	1.87e-05	0.000426	CbGpPWpGaD
Imatinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	1.86e-05	0.000423	CbGpPWpGaD
Imatinib—CA9—Metabolism—MED12—muscle cancer	1.84e-05	0.00042	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	1.83e-05	0.000416	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—MDM2—muscle cancer	1.81e-05	0.000412	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—MDM2—muscle cancer	1.81e-05	0.000412	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	1.81e-05	0.000412	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—MDM2—muscle cancer	1.8e-05	0.00041	CbGpPWpGaD
Imatinib—PDGFRA—Focal Adhesion—VEGFA—muscle cancer	1.8e-05	0.000409	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—MDM2—muscle cancer	1.8e-05	0.000409	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.79e-05	0.000407	CbGpPWpGaD
Imatinib—Nausea—Doxorubicin—muscle cancer	1.78e-05	0.000306	CcSEcCtD
Imatinib—LCK—Signaling by EGFR in Cancer—MDM2—muscle cancer	1.78e-05	0.000405	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—MDM2—muscle cancer	1.77e-05	0.000403	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIDINS220—muscle cancer	1.77e-05	0.000402	CbGpPWpGaD
Imatinib—ALB—Hemostasis—ANGPT2—muscle cancer	1.74e-05	0.000396	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—IGF2—muscle cancer	1.72e-05	0.000391	CbGpPWpGaD
Imatinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.72e-05	0.000391	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—FOXO1—muscle cancer	1.71e-05	0.00039	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—MDM2—muscle cancer	1.71e-05	0.000388	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD34—muscle cancer	1.7e-05	0.000386	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	1.69e-05	0.000385	CbGpPWpGaD
Imatinib—CA9—Metabolism—ENO2—muscle cancer	1.68e-05	0.000383	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—MDM2—muscle cancer	1.68e-05	0.000382	CbGpPWpGaD
Imatinib—CA3—Metabolism—PTGS2—muscle cancer	1.67e-05	0.000381	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD34—muscle cancer	1.65e-05	0.000376	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—FH—muscle cancer	1.65e-05	0.000375	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—FOXO1—muscle cancer	1.65e-05	0.000375	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	1.64e-05	0.000374	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—FH—muscle cancer	1.64e-05	0.000372	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—FH—muscle cancer	1.63e-05	0.000372	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—FOXO1—muscle cancer	1.62e-05	0.000369	CbGpPWpGaD
Imatinib—PDGFRB—Focal Adhesion—VEGFA—muscle cancer	1.62e-05	0.000369	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—FOXO1—muscle cancer	1.61e-05	0.000367	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	1.6e-05	0.000365	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—FOXO4—muscle cancer	1.59e-05	0.000361	CbGpPWpGaD
Imatinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.59e-05	0.000361	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—FH—muscle cancer	1.59e-05	0.000361	CbGpPWpGaD
Imatinib—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	1.58e-05	0.000358	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.57e-05	0.000358	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—KIT—muscle cancer	1.57e-05	0.000357	CbGpPWpGaD
Imatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—muscle cancer	1.56e-05	0.000355	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—FOXO1—muscle cancer	1.56e-05	0.000355	CbGpPWpGaD
Imatinib—ALB—Platelet degranulation—VEGFA—muscle cancer	1.55e-05	0.000353	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—MDM2—muscle cancer	1.54e-05	0.00035	CbGpPWpGaD
Imatinib—KIT—Disease—ENO2—muscle cancer	1.53e-05	0.000348	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—FOXO4—muscle cancer	1.53e-05	0.000347	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—FH—muscle cancer	1.52e-05	0.000346	CbGpPWpGaD
Imatinib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	1.48e-05	0.000337	CbGpPWpGaD
Imatinib—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	1.47e-05	0.000334	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—FOXO1—muscle cancer	1.46e-05	0.000333	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ENO2—muscle cancer	1.45e-05	0.00033	CbGpPWpGaD
Imatinib—CA9—Cellular responses to stress—TP53—muscle cancer	1.45e-05	0.000329	CbGpPWpGaD
Imatinib—ABL1—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.43e-05	0.000326	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—FOXO1—muscle cancer	1.42e-05	0.000324	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IGF2—muscle cancer	1.42e-05	0.000322	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—FOXO1—muscle cancer	1.4e-05	0.000319	CbGpPWpGaD
Imatinib—KIT—Disease—HMGA1—muscle cancer	1.39e-05	0.000317	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PTCH1—muscle cancer	1.39e-05	0.000316	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.37e-05	0.000313	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—TP53—muscle cancer	1.37e-05	0.000311	CbGpPWpGaD
Imatinib—LCK—Immune System—CD34—muscle cancer	1.36e-05	0.00031	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.35e-05	0.000308	CbGpPWpGaD
Imatinib—KIT—Immune System—FOXO4—muscle cancer	1.35e-05	0.000308	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—TP53—muscle cancer	1.35e-05	0.000307	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HMGA1—muscle cancer	1.32e-05	0.0003	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ENO2—muscle cancer	1.31e-05	0.000297	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.29e-05	0.000294	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—FOXO4—muscle cancer	1.28e-05	0.000291	CbGpPWpGaD
Imatinib—KIT—Disease—FOXO4—muscle cancer	1.25e-05	0.000284	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—KIT—muscle cancer	1.24e-05	0.000281	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—MDM2—muscle cancer	1.23e-05	0.000281	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—MDM2—muscle cancer	1.21e-05	0.000275	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FOXO4—muscle cancer	1.19e-05	0.000271	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.19e-05	0.00027	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—KIT—muscle cancer	1.19e-05	0.00027	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HMGA1—muscle cancer	1.19e-05	0.00027	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—FH—muscle cancer	1.18e-05	0.000269	CbGpPWpGaD
Imatinib—PDGFRA—Disease—FOXO4—muscle cancer	1.18e-05	0.000269	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—FOXO1—muscle cancer	1.17e-05	0.000267	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CNR1—muscle cancer	1.17e-05	0.000266	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.16e-05	0.000264	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—FOXO4—muscle cancer	1.15e-05	0.000262	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.15e-05	0.000262	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—FOXO1—muscle cancer	1.13e-05	0.000256	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—MDM2—muscle cancer	1.13e-05	0.000256	CbGpPWpGaD
Imatinib—ABL1—Immune System—FOXO4—muscle cancer	1.12e-05	0.000256	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KIT—muscle cancer	1.11e-05	0.000253	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KIT—muscle cancer	1.09e-05	0.000247	CbGpPWpGaD
Imatinib—CA14—Metabolism—PTGS2—muscle cancer	1.08e-05	0.000245	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—KIT—muscle cancer	1.07e-05	0.000243	CbGpPWpGaD
Imatinib—PDGFRB—Disease—FOXO4—muscle cancer	1.06e-05	0.000242	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.06e-05	0.000241	CbGpPWpGaD
Imatinib—CA6—Metabolism—PTGS2—muscle cancer	1.05e-05	0.000239	CbGpPWpGaD
Imatinib—LCK—Disease—ENO2—muscle cancer	1.05e-05	0.000238	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—VEGFA—muscle cancer	1.03e-05	0.000234	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—MDM2—muscle cancer	1.03e-05	0.000234	CbGpPWpGaD
Imatinib—ALB—Metabolism—FH—muscle cancer	1.02e-05	0.000232	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTCH1—muscle cancer	1.02e-05	0.000231	CbGpPWpGaD
Imatinib—KIT—Immune System—FOXO1—muscle cancer	9.98e-06	0.000227	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—MDM2—muscle cancer	9.88e-06	0.000225	CbGpPWpGaD
Imatinib—CA7—Metabolism—PTGS2—muscle cancer	9.81e-06	0.000223	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—MDM2—muscle cancer	9.74e-06	0.000222	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	9.62e-06	0.000219	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IGF2—muscle cancer	9.57e-06	0.000218	CbGpPWpGaD
Imatinib—LCK—Disease—HMGA1—muscle cancer	9.52e-06	0.000217	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—FOXO1—muscle cancer	9.45e-06	0.000215	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	9.35e-06	0.000213	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—MED12—muscle cancer	9.32e-06	0.000212	CbGpPWpGaD
Imatinib—LCK—Immune System—FOXO4—muscle cancer	9.25e-06	0.000211	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—MED12—muscle cancer	9.24e-06	0.00021	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—MED12—muscle cancer	9.23e-06	0.00021	CbGpPWpGaD
Imatinib—KIT—Disease—FOXO1—muscle cancer	9.22e-06	0.00021	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—FH—muscle cancer	9.14e-06	0.000208	CbGpPWpGaD
Imatinib—CA12—Metabolism—PTGS2—muscle cancer	9.09e-06	0.000207	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.04e-06	0.000206	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—MED12—muscle cancer	8.96e-06	0.000204	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KIT—muscle cancer	8.94e-06	0.000203	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	8.93e-06	0.000203	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—FH—muscle cancer	8.92e-06	0.000203	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FOXO1—muscle cancer	8.81e-06	0.0002	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—MDM2—muscle cancer	8.77e-06	0.0002	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FOXO4—muscle cancer	8.74e-06	0.000199	CbGpPWpGaD
Imatinib—PDGFRA—Disease—FOXO1—muscle cancer	8.73e-06	0.000199	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	8.67e-06	0.000197	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	8.61e-06	0.000196	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—MED12—muscle cancer	8.6e-06	0.000196	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KIT—muscle cancer	8.58e-06	0.000195	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CNR1—muscle cancer	8.58e-06	0.000195	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—MDM2—muscle cancer	8.55e-06	0.000195	CbGpPWpGaD
Imatinib—LCK—Disease—FOXO4—muscle cancer	8.54e-06	0.000194	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—FOXO1—muscle cancer	8.51e-06	0.000194	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ENO2—muscle cancer	8.5e-06	0.000193	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IGF2—muscle cancer	8.46e-06	0.000193	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ENO2—muscle cancer	8.43e-06	0.000192	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	8.42e-06	0.000192	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ENO2—muscle cancer	8.41e-06	0.000191	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—FH—muscle cancer	8.41e-06	0.000191	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—FH—muscle cancer	8.33e-06	0.00019	CbGpPWpGaD
Imatinib—ABL1—Immune System—FOXO1—muscle cancer	8.3e-06	0.000189	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	8.27e-06	0.000188	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ENO2—muscle cancer	8.17e-06	0.000186	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	8.12e-06	0.000185	CbGpPWpGaD
Imatinib—PDGFRB—Disease—FOXO1—muscle cancer	7.86e-06	0.000179	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ENO2—muscle cancer	7.84e-06	0.000178	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	7.45e-06	0.00017	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—VEGFA—muscle cancer	7.35e-06	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	7.32e-06	0.000166	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—VEGFA—muscle cancer	7.21e-06	0.000164	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KIT—muscle cancer	7.2e-06	0.000164	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—FH—muscle cancer	7.12e-06	0.000162	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—MDM2—muscle cancer	7.04e-06	0.00016	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IGF2—muscle cancer	7.01e-06	0.00016	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTCH1—muscle cancer	6.96e-06	0.000158	CbGpPWpGaD
Imatinib—CA2—Metabolism—PTGS2—muscle cancer	6.95e-06	0.000158	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	6.89e-06	0.000157	CbGpPWpGaD
Imatinib—LCK—Immune System—FOXO1—muscle cancer	6.83e-06	0.000155	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.78e-06	0.000154	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—MDM2—muscle cancer	6.76e-06	0.000154	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KIT—muscle cancer	6.71e-06	0.000153	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MED12—muscle cancer	6.68e-06	0.000152	CbGpPWpGaD
Imatinib—CA1—Metabolism—PTGS2—muscle cancer	6.66e-06	0.000152	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KIT—muscle cancer	6.65e-06	0.000151	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	6.64e-06	0.000151	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KIT—muscle cancer	6.49e-06	0.000148	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FOXO1—muscle cancer	6.46e-06	0.000147	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.39e-06	0.000145	CbGpPWpGaD
Imatinib—ABL1—Immune System—KIT—muscle cancer	6.32e-06	0.000144	CbGpPWpGaD
Imatinib—LCK—Disease—FOXO1—muscle cancer	6.31e-06	0.000144	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	6.11e-06	0.000139	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO2—muscle cancer	6.09e-06	0.000139	CbGpPWpGaD
Imatinib—KIT—Immune System—MDM2—muscle cancer	5.99e-06	0.000136	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KIT—muscle cancer	5.99e-06	0.000136	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FOXO4—muscle cancer	5.98e-06	0.000136	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	5.98e-06	0.000136	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—muscle cancer	5.94e-06	0.000135	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CNR1—muscle cancer	5.87e-06	0.000134	CbGpPWpGaD
Imatinib—CA9—Metabolism—PTGS2—muscle cancer	5.86e-06	0.000133	CbGpPWpGaD
Imatinib—ALB—Metabolism—MED12—muscle cancer	5.75e-06	0.000131	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MDM2—muscle cancer	5.67e-06	0.000129	CbGpPWpGaD
Imatinib—KIT—Disease—MDM2—muscle cancer	5.53e-06	0.000126	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	5.5e-06	0.000125	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—FH—muscle cancer	5.5e-06	0.000125	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—muscle cancer	5.45e-06	0.000124	CbGpPWpGaD
Imatinib—KIT—Disease—PTGS2—muscle cancer	5.33e-06	0.000121	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MDM2—muscle cancer	5.29e-06	0.00012	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO2—muscle cancer	5.25e-06	0.000119	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MDM2—muscle cancer	5.24e-06	0.000119	CbGpPWpGaD
Imatinib—LCK—Immune System—KIT—muscle cancer	5.21e-06	0.000118	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MED12—muscle cancer	5.17e-06	0.000118	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.12e-06	0.000117	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MDM2—muscle cancer	5.11e-06	0.000116	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTGS2—muscle cancer	5.05e-06	0.000115	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MED12—muscle cancer	5.04e-06	0.000115	CbGpPWpGaD
Imatinib—ABL1—Immune System—MDM2—muscle cancer	4.98e-06	0.000113	CbGpPWpGaD
Imatinib—LCK—Disease—KIT—muscle cancer	4.81e-06	0.000109	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF2—muscle cancer	4.8e-06	0.000109	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MED12—muscle cancer	4.75e-06	0.000108	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MDM2—muscle cancer	4.72e-06	0.000107	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MED12—muscle cancer	4.71e-06	0.000107	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO2—muscle cancer	4.71e-06	0.000107	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KIT—muscle cancer	4.66e-06	0.000106	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO2—muscle cancer	4.6e-06	0.000105	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTGS2—muscle cancer	4.55e-06	0.000103	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—muscle cancer	4.49e-06	0.000102	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FOXO1—muscle cancer	4.42e-06	0.000101	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO2—muscle cancer	4.33e-06	9.85e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO2—muscle cancer	4.29e-06	9.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KIT—muscle cancer	4.19e-06	9.54e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.1e-06	9.33e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MDM2—muscle cancer	4.1e-06	9.33e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MED12—muscle cancer	4.02e-06	9.16e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—muscle cancer	4.01e-06	9.13e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MDM2—muscle cancer	3.87e-06	8.81e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MDM2—muscle cancer	3.79e-06	8.61e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.68e-06	8.38e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—muscle cancer	3.67e-06	8.35e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	3.67e-06	8.34e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—muscle cancer	3.65e-06	8.3e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—muscle cancer	3.55e-06	8.08e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIT—muscle cancer	3.37e-06	7.66e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.36e-06	7.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	3.3e-06	7.52e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MED12—muscle cancer	3.11e-06	7.07e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—muscle cancer	3.03e-06	6.9e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—muscle cancer	2.96e-06	6.74e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—muscle cancer	2.94e-06	6.69e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—muscle cancer	2.93e-06	6.68e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—muscle cancer	2.93e-06	6.67e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.87e-06	6.53e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—muscle cancer	2.84e-06	6.47e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—muscle cancer	2.83e-06	6.44e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	2.78e-06	6.34e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—muscle cancer	2.73e-06	6.21e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—muscle cancer	2.68e-06	6.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—muscle cancer	2.65e-06	6.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	2.51e-06	5.71e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—muscle cancer	2.22e-06	5.06e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—muscle cancer	2.12e-06	4.83e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—muscle cancer	2.1e-06	4.79e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—muscle cancer	2.01e-06	4.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—muscle cancer	1.9e-06	4.31e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—muscle cancer	1.83e-06	4.16e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—muscle cancer	1.64e-06	3.73e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—muscle cancer	1.6e-06	3.64e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—muscle cancer	1.52e-06	3.46e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—muscle cancer	1.51e-06	3.43e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—muscle cancer	1.5e-06	3.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—muscle cancer	1.28e-06	2.91e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—muscle cancer	9.86e-07	2.24e-05	CbGpPWpGaD
